Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.30|
|52 Week High||US$6.68|
|52 Week Low||US$53.75|
|1 Month Change||-4.05%|
|3 Month Change||-18.63%|
|1 Year Change||-80.32%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-48.01%|
Recent News & Updates
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
|IMVT||US Biotechs||US Market|
Return vs Industry: IMVT underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: IMVT underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: IMVT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: IMVT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York.
Immunovant Fundamentals Summary
|IMVT fundamental statistics|
Is IMVT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMVT income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.97|
|Net Profit Margin||0.00%|
How did IMVT perform over the long term?See historical performance and comparison
Is Immunovant undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMVT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMVT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMVT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: IMVT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMVT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMVT is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (2.9x).
How is Immunovant forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMVT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMVT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMVT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMVT is forecast to have no revenue next year.
High Growth Revenue: IMVT is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMVT is forecast to be unprofitable in 3 years.
How has Immunovant performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMVT is currently unprofitable.
Growing Profit Margin: IMVT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMVT is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.
Accelerating Growth: Unable to compare IMVT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: IMVT has a negative Return on Equity (-30.42%), as it is currently unprofitable.
How is Immunovant's financial position?
Financial Position Analysis
Short Term Liabilities: IMVT's short term assets ($384.8M) exceed its short term liabilities ($20.5M).
Long Term Liabilities: IMVT's short term assets ($384.8M) exceed its long term liabilities ($2.0M).
Debt to Equity History and Analysis
Debt Level: IMVT is debt free.
Reducing Debt: IMVT had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMVT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IMVT has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 2.3% each year.
What is Immunovant current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMVT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMVT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMVT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMVT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMVT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pete Salzmann (53 yo)
Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer of Immunovant, Inc. since June 2019 and has been its Director since December 2019. Dr. Salzmann serves as Independent Dir...
CEO Compensation Analysis
Compensation vs Market: Pete's total compensation ($USD15.38M) is above average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Pete's compensation has increased whilst the company is unprofitable.
Experienced Management: IMVT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: IMVT's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IMVT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.2%.
Immunovant, Inc.'s employee growth, exchange listings and data sources
- Name: Immunovant, Inc.
- Ticker: IMVT
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$954.491m
- Shares outstanding: 115.00m
- Website: https://immunovant.com
Number of Employees
- Immunovant, Inc.
- 320 West 37th Street
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 22:15|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.